Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

10.96 -0.03 (-0.27%)
Streaming Delayed Price Updated: 12:01 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics

< Previous 1 2 3 4 5 Next >
Why Are Amicus Therapeutics Shares Trading Higher Today?
The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Cellectar Biosciences (NASDAQ:CLRB 
Via Benzinga
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail. 
Via The Motley Fool
Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript
FOLD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents
The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable... 
Via Benzinga
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
Amicus Therapeutics Insights: Return On Capital Employed
Amicus Therapeutics (NASDAQ:FOLD) reported Q1 sales of $66.40 million. Earnings fell to a loss of $52.58 million, resulting in a 18.31% decrease from last quarter. In Q4, Amicus... 
Via Benzinga
Looking Into Amicus Therapeutics's Return On Capital Employed
During Q1, Amicus Therapeutics (NASDAQ:FOLD) brought in sales totaling $66.40 million. However, earnings decreased 18.31%, resulting in a loss of $52.58 million. In Q4, Amicus... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021
Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript
FOLD earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Amicus Therapeutics Q1 Earnings
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% over... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,... 
Via Benzinga
Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
Amicus Therapeutics Inc (NASDAQ: FOLD) has completed a Type B Pre-Biologics License Application (BLA) meeting with the FDA for AT-GAA (cipaglucosidase alfa co... 
Via Benzinga
Exposures Product Safety
Why Amicus Therapeutics Stock Is Soaring Today
Investors cheered an analyst's upgrade of the biotech stock. 
Via The Motley Fool
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021
Upgrades For Cardlytics Inc (NASDAQ:CDLX), Craig-Hallum upgraded the previous rating of Hold to Buy. For the fourth quarter, Cardlytics had an EPS of $0.05, compared to... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.